Metreleptin for Subcutaneous Injection Post-Marketing Surveillance

Metreleptin for Subcutaneous Injection Post-Marketing Surveillance - Metreleptin for Subcutaneous Injection Post-Marketing Surveillance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051667

Enrollment

Registered

2023-07-31

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipodystrophy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who were administrated Metreleptin

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety: Unexpected adverse drug reactions Incidence of adverse drug reactions	—

Secondary

Measure	Time frame
Efficacy: The mean value and the rate of change of HbA1c and blood triglycerides at each observation points	—

Countries

Japan

Contacts

Public ContactTomohisa Hata

Shionogi & Co., Ltd. Pharmacovigilance Department

tomohisa.hata@shionogi.co.jp+81-70-7812-6803

Outcome results